The 127% YoY revenue growth and accelerating patient adds (42,250+) confirm Rezdiffra's blockbuster trajectory. The EPS beat vs consensus is significant, but the widening net loss and $54.3M in one-time BD costs warrant monitoring. Watch for Q2 2026 patient adds and any updates on the oral GLP-1 Phase 1 initiation. The siRNA deal with Arrowhead adds pipeline optionality but near-term focus remains on Rezdiffra's commercial ramp.
MDGL drugs
MDGL drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 6 $539.73entry
- T+1 · 6mo ago −0.90%α −0.57% · $534.86
- T+5 · 6mo ago −5.46%α −6.59% · $510.26
- T+20 · 6mo ago −9.56%α −12.34% · $488.15
- T+60 · 4mo ago −13.42%α −15.48% · $467.32
Price Chart
How similar events traded
Executive Summary
Madrigal Pharmaceuticals reported Q1 2026 Rezdiffra net sales of $311.3M (+127% YoY), beating consensus revenue estimates of $300.9M. The company posted a GAAP net loss of $94.4M (-$3.25/share), which was narrower than the consensus EPS estimate of -$4.14, driven by strong commercial execution and 42,250+ patients on therapy. Management highlighted blockbuster status on a trailing-12-month basis and a rapidly expanding MASH market, but the company remains unprofitable with rising operating expenses.
Key Financial Metrics
Key Facts
- Q1 2026 Rezdiffra net sales of $311.3M, up 127% YoY from $137.3M
- GAAP net loss of $94.4M (-$3.25/share) vs consensus -$4.14 (38% beat)
- 42,250+ patients on Rezdiffra as of March 31, 2026, up 2.5x from Q1 2025
- Cash, equivalents, and marketable securities of $817.9M as of March 31, 2026
- Licensed clinical-stage siRNA asset (ARO-PNPLA3) from Arrowhead Pharmaceuticals on May 5, 2026
- Operating expenses of $404.1M included $54.3M in one-time upfront business development costs
- MGL-2086 (oral GLP-1) Phase 1 trial on track to initiate in Q2 2026
Financial Impact
Revenue beat consensus by ~$10.4M (3.5%); EPS beat by $0.89 (21.5% vs consensus -$4.14). Net loss widened YoY due to $54.3M in upfront BD expenses.
Risk Factors
- Net loss widened to $94.4M from $73.2M YoY, driven by $54.3M in upfront BD expenses
- Operating expenses grew 87% YoY to $404.1M, outpacing revenue growth
- Cash burn: cash decreased $170.7M from Dec 2025 ($988.6M) to March 2026 ($817.9M)
- Dependence on single product (Rezdiffra) for all revenue
- Potential competitive pressure from other MASH therapies in development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-030896 |
| Document: mdgl-20260506.htm | 0001628280-26-030896 |
| Document: 0001628280-26-030896-index-headers.html | 0001628280-26-030896 |
| Document: 0001628280-26-030896-index.html | 0001628280-26-030896 |
| Document: 0001628280-26-030896.txt | 0001628280-26-030896 |
| 8-K Data (Synthetic) | 0001628280-26-030896 |
Track record
18 reports on MDGL
3 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +10.26% at T+20 after the Jul 30, 2026 report. 3 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry price pending
- Nov 6, 202610d ago SC 13D/A Neutral 3/10 Entry $432.79 to $423.96 Now $423.96 −2.04% ▼ −2.04% −0.35% vs SPY
- Nov 6, 202610d ago Insider Buy Bullish 5/10 Entry $432.79 to $423.96 Now $423.96 −2.04% ▼ −2.04% −0.35% vs SPY
- Nov 6, 202610d ago Insider Cluster Bullish 5/10 Entry $432.79 to $423.96 Now $423.96 −2.04% ▼ −2.04% −0.35% vs SPY
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $432.79 to $423.96 Now $423.96 −2.04% ▼ −2.04% −0.35% vs SPY
- Nov 5, 202611d ago Institutional Cluster Mixed 3/10 Entry $400.10 to $425.21 Now $423.96 +5.96% ▲ +6.28% +2.99% vs SPY
- Nov 5, 202611d ago Press Release Bullish 5/10 Entry $400.10 to $425.21 Now $423.96 +5.96% ▲ +6.28% +2.99% vs SPY
- Nov 3, 202613d ago 8-K Bullish 7/10 No price data
- Nov 3, 202613d ago Press Release Bullish 6/10 Entry $396.32 to $432.60 Now $423.96 +6.97% ▲ +9.15% +9.74% vs SPY
- Aug 12, 202613w ago 8-K Neutral 3/10 Entry $536.20 to $540.16 Now $423.96 −20.93% ▲ +0.74% +1.18% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers